Literature DB >> 21070524

Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.

J Sausville1, M Naslund.   

Abstract

Benign prostatic hyperplasia (BPH) and prostate cancer (CaP) are major sources of morbidity in older men. Management of these disorders has evolved considerably in recent years. This article provides a focused overview of BPH and CaP management aimed at primary care physicians. Current literature pertaining to BPH and CaP is reviewed and discussed. The management of BPH has been influenced by the adoption of effective medical therapies; nonetheless, surgical intervention remains a valid option for many men. This can be accomplished with well-established standards such as transurethral resection of the prostate or with minimally invasive techniques. Prostate cancer screening remains controversial despite the recent publication of two large clinical trials. Not all prostate cancers necessarily need to be treated. Robot-assisted prostatectomy is a new and increasingly utilised technique for CaP management, although open radical retropubic prostatectomy is the oncological reference standard. The ageing of the population of the developed world means that primary care physicians will see an increasing number of men with BPH and CaP. Close collaboration between primary care physicians and urologists offers the key to successful management of these disorders.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070524     DOI: 10.1111/j.1742-1241.2010.02534.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  10 in total

1.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

Review 2.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 3.  Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  Prostatic surgery associated acute kidney injury.

Authors:  Elerson Carlos Costalonga; Verônica Torres Costa E Silva; Renato Caires; James Hung; Luis Yu; Emmanuel A Burdmann
Journal:  World J Nephrol       Date:  2014-11-06

Review 5.  Pelvic ultrasound evaluation for benign prostatic hyperplasia: prediction of obstruction.

Authors:  Daniel B Rukstalis
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

6.  Prostate cancer in primary care, port harcourt, Nigeria.

Authors:  Andrew Bock-Oruma; S Oghu Iboh; Dan-Jumbo Prince
Journal:  J Family Med Prim Care       Date:  2014-04

7.  Association of Some Polymorphisms in the VDR Gene, CYP17 Gene and SRD5A2 Gene and Prostate Cancer among Lebanesezzm321990Men

Authors:  Asmahan A El Ezzi; Vladyslav G Boyko; Monika T Baker; Wissam R Zaidan; Kalim M Hraiki; Mohammad A El Saidi; Ruhul H Kuddus
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

8.  LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese Population.

Authors:  Yang Jiao; Li Wang; Xin Gu; Sha Tao; Lu Tian; Rong Na; Zhuo Chen; Jian Kang; Siqun L Zheng; Jianfeng Xu; Jielin Sun; Jun Qi
Journal:  Int J Mol Sci       Date:  2013-04-24       Impact factor: 5.923

9.  Comparative effects of Yi Jin Jing versus Tai Chi exercise training on benign prostatic hyperplasia-related outcomes in older adults: study protocol for a randomized controlled trial.

Authors:  XiangYun Liu; Guoyuan Huang; Peijie Chen; Yong Li; JiuLin Xiang; Ting Chen; Ru Wang
Journal:  Trials       Date:  2016-07-16       Impact factor: 2.279

10.  Incidence and risk factors of postoperative delirium in elderly patients undergoing transurethral resection of prostate: a prospective cohort study.

Authors:  Peng Xue; Ziyu Wu; Kunpeng Wang; Chuanquan Tu; Xiangbo Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-12       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.